azomycin has been researched along with Glioblastoma in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (47.83) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 2 (8.70) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Brenner, AJ; Fichtel, L; Floyd, J; Huang, S; Kanakia, KP; Lee, EQ; Michalek, J; Reardon, D; Wen, PY | 1 |
| Brenner, A; Caflisch, L; Cavazos, D; Fichtel, L; Floyd, J; Gruslova, A; Hart, CP; Huang, S; Kroll, S; Liu, Y; Lodi, A; Sun, JD; Tiziani, S; Zuniga, R | 1 |
| Bolcaen, J; Boterberg, T; De Meulenaere, V; De Vos, F; Deblaere, K; Descamps, B; Donche, S; Goethals, I; Kalala, JP; Kersemans, K; Van den Broecke, C; Vanhove, C; Verhoeven, J | 1 |
| Beppu, T; Ehara, S; Fujiwara, S; Iwata, R; Kudo, K; Matsuura, H; Ogasawara, K; Sasaki, M; Sasaki, T; Sera, K; Sugai, T; Takai, Y; Terasaki, K; Uesugi, N; Yamada, N | 1 |
| Belloli, S; Brioschi, A; Calderoni, S; Fazio, F; Mauro, A; Monterisi, C; Moresco, RM; Pagani, A; Politi, LS; Raccagni, I; Ronchetti, F; Zara, G; Zenga, F | 1 |
| Beppu, T; Ehara, S; Iwata, R; Mtsuura, H; Ogasawara, K; Sasaki, M; Sasaki, T; Saura, H; Takai, Y; Terasaki, K | 1 |
| Chen, X; Duan, Y; Gao, R; Liang, M; Ou, Y; Wang, L; Wang, P; Wang, Z; Yuan, Y; Zhu, H; Zou, M | 1 |
| Higano, S; Iwata, R; Kanamori, M; Kumabe, T; Saito, R; Shibahara, I; Sonoda, Y; Takai, Y; Takanami, K; Tominaga, T; Watanabe, M | 1 |
| Delattre, JY; Goldman, S; Petrirena, GJ | 1 |
| Brown, JM; Vordermark, D | 1 |
| Boerman, OC; Bussink, J; Kaanders, JH; Laverman, P; Lok, J; Oyen, WJ; Philippens, M; Troost, EG; van der Kogel, AJ | 1 |
| Fulton, DS; Geggie, PH; Johnson, E; Mielke, B; Moody, J; Muller, PJ; Shin, KH; Tanasichuk, H; Thomas, H; Urtasun, RC | 1 |
| Kärcher, KH; Kogelnik, HD; Stadler, B; Szepesi, T | 1 |
| Agboola, O; Feldstein, ML; Mielke, B; Miller, JD; Partington, J; Russell, DB; Tanasichuk, H; Urtasun, R | 1 |
| Abe, M; Dodo, Y; Hamanaka, D; Hiraoka, M; Nishidai, T; Ono, K; Takahashi, M | 1 |
| Chapman, JD; Golberg, LE; Groshar, D; Hoskinson, M; Mannan, RH; McEwan, AJ; Mercer, JR; Parliament, MB; Urtasun, RC; Wiebe, LI | 1 |
| Fowler, JF | 1 |
| Chapman, D; Koziol, D; Partington, J; Rabin, H; Urtasun, RC | 1 |
| Bleehen, NM; Freedman, LS; Stenning, SP | 1 |
| Bleehen, NM; Newman, HF; Ward, R; Workman, P | 1 |
| Awschalom, M; Cohen, L; Hendrickson, FR; Kurup, PD; Mansell, J; Nelson, JS; Pajak, TF; Rosenberg, I; Ten Haken, RK | 1 |
| Ganz, JC; Hagen, S; Hatlevoll, R; Kristiansen, K; Lindegaard, KF; Mella, O; Nesbakken, R; Ringkjöb, R; Rosengren, B; Torvik, A | 1 |
1 review(s) available for azomycin and Glioblastoma
| Article | Year |
|---|---|
Advances in PET imaging of brain tumors: a referring physician's perspective.
Topics: Brain Neoplasms; Carbon Radioisotopes; Dideoxynucleosides; Fluorine Radioisotopes; Glioblastoma; Glioma; Humans; Methionine; Nitroimidazoles; Positron-Emission Tomography; Radiography; Radiopharmaceuticals | 2011 |
10 trial(s) available for azomycin and Glioblastoma
| Article | Year |
|---|---|
Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma.
Topics: Adult; Aged; Bevacizumab; Female; Glioblastoma; Humans; Male; Middle Aged; Nitroimidazoles; Phosphoramide Mustards; Young Adult | 2021 |
Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Humans; Hypoxia; Male; Middle Aged; Neoplasm Recurrence, Local; Nitroimidazoles; Phosphoramide Mustards; Prognosis; Salvage Therapy | 2018 |
Standardized uptake value in high uptake area on positron emission tomography with 18F-FRP170 as a hypoxic cell tracer correlates with intratumoral oxygen pressure in glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Nitroimidazoles; Oxygen; Positron-Emission Tomography; Pressure | 2014 |
Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new 18F-labeled 2-nitroimidazole analog.
Topics: Adult; Aged; Astrocytoma; Biopsy; Brain Neoplasms; Carbon Isotopes; Cell Division; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia, Brain; Immunohistochemistry; Magnetic Resonance Imaging; Male; Methionine; Middle Aged; Nitroimidazoles; Oligodendroglioma; Positron-Emission Tomography; Protons; Radiopharmaceuticals | 2010 |
Misonidazole combined with hyperfractionation in the management of malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Glioblastoma; Glioma; Humans; Middle Aged; Misonidazole; Nitroimidazoles; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Random Allocation | 1984 |
Misonidazole and irradiation in the treatment of high-grade astrocytomas: further report of the Vienna Study Group.
Topics: Brain Neoplasms; Clinical Trials as Topic; Female; Glioblastoma; Humans; Male; Middle Aged; Misonidazole; Nitroimidazoles; Prognosis; Radiation-Sensitizing Agents; Random Allocation | 1984 |
Radiation and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial.
Topics: Adult; Aged; Cerebellar Neoplasms; Clinical Trials as Topic; Glioblastoma; Humans; Metronidazole; Middle Aged; Misonidazole; Nitroimidazoles; Random Allocation | 1982 |
A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of grades 3 and 4 astrocytomas. A report from the MRC Working Party on misonidazole in gliomas.
Topics: Adolescent; Adult; Aged; Cerebellar Neoplasms; Clinical Trials as Topic; Double-Blind Method; Glioblastoma; Humans; Kinetics; Middle Aged; Misonidazole; Nitroimidazoles; Patient Compliance; Random Allocation | 1983 |
A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party.
Topics: Adolescent; Adult; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Nitroimidazoles; Prognosis; Random Allocation | 1989 |
Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of
Topics: Actuarial Analysis; Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; Misonidazole; Nitroimidazoles; Radiotherapy Dosage; Random Allocation; Scandinavian and Nordic Countries; Telencephalon | 1985 |
12 other study(ies) available for azomycin and Glioblastoma
| Article | Year |
|---|---|
Technical feasibility of [
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Feasibility Studies; Female; Glioblastoma; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Image-Guided; Rats, Inbred F344; Treatment Outcome; Tumor Burden; Tyrosine | 2019 |
Characterization of biological features of a rat F98 GBM model: a PET-MRI study with [18F]FAZA and [18F]FDG.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Disease Models, Animal; Fluorodeoxyglucose F18; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Nitroimidazoles; Positron-Emission Tomography; Rats; Survival Analysis | 2013 |
High-uptake areas on positron emission tomography with the hypoxic radiotracer (18)F-FRP170 in glioblastomas include regions retaining proliferative activity under hypoxia.
Topics: Adult; Aged; Brain; Brain Neoplasms; Female; Glioblastoma; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
DYT-40, a novel synthetic 2-styryl-5-nitroimidazole derivative, blocks malignant glioblastoma growth and invasion by inhibiting AEG-1 and NF-κB signaling pathways.
Topics: Animals; Antineoplastic Agents; Cell Adhesion Molecules; Cell Line, Tumor; Disease Models, Animal; Glioblastoma; Histocytochemistry; Humans; Immunohistochemistry; Membrane Proteins; Microscopy; NF-kappa B; Nitroimidazoles; Rats; RNA-Binding Proteins; Signal Transduction; Treatment Outcome | 2016 |
Evaluation of hypoxia-inducible factor-1alpha (HIF-1alpha) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies.
Topics: Animals; Biomarkers, Tumor; Blotting, Western; Cell Hypoxia; Female; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, SCID; Neoplasm Transplantation; Nitroimidazoles; Oxygen; Transcription Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
Topics: Animals; Autoradiography; Carcinoma, Squamous Cell; Cell Hypoxia; Fluorine Radioisotopes; Glioblastoma; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Radionuclide Imaging | 2006 |
[Intraoperative radiotherapy in combination with misonidazole; with special reference to the drug concentrations in tumors and normal tissues and to the initial effect of the treatment].
Topics: Adult; Colonic Neoplasms; Glioblastoma; Humans; Intraoperative Care; Intraoperative Period; Middle Aged; Misonidazole; Nitroimidazoles; Rectal Neoplasms; Stomach Neoplasms | 1983 |
Imaging tumor hypoxia and tumor perfusion.
Topics: Brain Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Hypoxia; Female; Glioblastoma; Head and Neck Neoplasms; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Nitroimidazoles; Organotechnetium Compounds; Oximes; Sarcoma; Soft Tissue Neoplasms; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon | 1993 |
Developments in radiotherapy other than heavy particle beams.
Topics: Animals; Brain Neoplasms; Energy Transfer; Fast Neutrons; Female; Glioblastoma; Hot Temperature; Humans; Mammary Neoplasms, Experimental; Metronidazole; Mice; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; X-Rays | 1977 |
New side effect of the hypoxic cell sensitizer, misonidazole.
Topics: Aged; Brain Neoplasms; Drug Eruptions; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Misonidazole; Nitroimidazoles | 1979 |
Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Topics: Brain Neoplasms; Drug Therapy, Combination; Etanidazole; Glioblastoma; Humans; Nitroimidazoles; Radiation-Sensitizing Agents | 1988 |
Fast neutrons and misonidazole for malignant astrocytomas.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Misonidazole; Neutrons; Nitroimidazoles | 1985 |